1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,710 | 3,960 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | HSI Closes Up 44 Pts in Half-day Session as SMIC Leaps 3%+; BIOCYTOGEN-B Soars 20% | 3 | AASTOCKS | ||
| Mi | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT | 2 | HKEx | ||
| Mi | BIOCYTOGEN-B Leapfrogs 20%+ after Being Added to Southbound Stock Connect | 3 | AASTOCKS | ||
| Mi | BIOCYTOGEN-B Added to List of Securities Eligible for Southbound Stock Connect, Effective Today | 3 | AASTOCKS | ||
| 10.12. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Börsengang am STAR-Markt ab und wird zum ersten globalen Arzneimittelentwickler mit "H+A"-Status | 438 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine... ► Artikel lesen | |
| 10.12. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 487 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing... ► Artikel lesen | |
| 10.12. | BIOCYTOGEN-B (02315): NEXT DAY DISCLOSURE RETURNS | 4 | HKEx | ||
| 10.12. | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 477 | Business Wire | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful... ► Artikel lesen | |
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 10.12. | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE STRATEGY COMMITTEE | 2 | HKEx | ||
| 10.12. | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE REMUNERATION AND EVALUATION COMMITTEE | 2 | HKEx | ||
| 09.12. | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE NOMINATION COMMITTEE | 1 | HKEx | ||
| 09.12. | BIOCYTOGEN-B (02315): RULES OF PROCEDURE FOR THE AUDIT COMMITTEE | 1 | HKEx | ||
| 09.12. | BIOCYTOGEN-B (02315): ARTICLES OF ASSOCIATION | 3 | HKEx | ||
| 09.12. | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 2 | HKEx | ||
| 09.12. | BIOCYTOGEN-B (02315): INSIDE INFORMATION COMPLETION OF THE ISSUE OF A SHARES; AND RESIGNATION OF EXECUTIVE DIRECTOR AND ELECTION OF EMPLOYEE DIRECTOR | 1 | HKEx | ||
| 05.12. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: IDE034, ein bispezifisches ADC, das von Biocytogen an IDEAYA lizenziert wurde, erhält IND-Zulassung von der FDA | 270 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), gab bekannt, dass sein Partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), ein Unternehmen für Präzisionsonkologie, die Genehmigung... ► Artikel lesen | |
| 05.12. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: IDE034, a Bispecific ADC Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance | 1.043 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision oncology company, has received the clearance... ► Artikel lesen | |
| 05.12. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT BUSINESS PARTNER IDEAYA RECEIVED FDA CLEARANCE OF IND APPLICATION FOR IDE034 | 1 | HKEx | ||
| 26.11. | BIOCYTOGEN-B (02315): INSIDE INFORMATION DETERMINATION OF THE OFFER SIZE AND OFFER PRICE FOR THE A SHARE OFFERING | 1 | HKEx | ||
| 19.11. | BIOCYTOGEN-B (02315): INSIDE INFORMATION THE PROGRESS OF PROPOSED ISSUE OF A SHARES FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS | 1 | HKEx |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,025 | +16,67 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| BIOFRONTERA | 2,430 | +4,29 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| CLINUVEL | 7,250 | +0,90 % | Clinuvel Pharmaceuticals Limited: CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies | EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery... ► Artikel lesen | |
| EDITAS MEDICINE | 1,974 | -4,04 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 0,100 | 0,00 % | XFRA JJ80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,560 | -7,25 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 2,390 | -1,44 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| CLEAN HARBORS | 201,30 | -0,89 % | Why Clean Harbors Stock Triumphed on Tuesday | ||
| SPERO THERAPEUTICS | 1,894 | +0,42 % | Spero Therapeutics, Inc.: Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis | CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare... ► Artikel lesen | |
| MESOBLAST | 1,530 | +1,32 % | Mesoblast, Invictus, PLS Group, more: The 10 stocks that got investor chins wagging on HotCopper in CY25 | ||
| CSTONE PHARMACEUTICALS | 0,625 | 0,00 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE INCLUSION OF GAVRETO (PRALSETINIB) IN THE 2025 NATIONAL REIMBURSEMENT DRUG LIST | ||
| PROTALIX BIOTHERAPEUTICS | 1,480 | -0,67 % | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG: Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement | EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
/ Key word(s): Agreement
Secarna Pharmaceuticals and Protalix Biotherapeutics Enter into Collaboration and Option Agreement
17.12.2025... ► Artikel lesen | |
| LIR LIFE SCIENCES | 1,000 | +5,26 % | EQS-Media: LIR Life Sciences Corp.: Proprietäre Technologie mit erheblichem Marktpotenzial: LIR Life Sciences positioniert sich als innovativer Anbieter | EQS-Media / 23.12.2025 / 15:55 CET/CEST
Lir Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR Life Sciences oder das Unternehmen, entwickelt sich zu einem führenden Anbieter im... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 103,37 | -2,32 % | Palvella Therapeutics Inc.: Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) for the Treatment of Angiokeratomas | Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need With Fast Track designation, QTORIN rapamycin for... ► Artikel lesen | |
| PURPLE BIOTECH | 0,706 | 0,00 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update | Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,060 Euro und damit -3,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.